MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
EDSA - Edesa Biotech Inc
$6.54
-0.12(-1.80%)6:00:01 PM 11/26/2021
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
Peers

Related Peers

Stock news

    11/4/2021EDSA
    Edesa Biotech Extends COVID-19 Clinical Study to Poland

    * Expansion to European Union country follows favorable Phase 2 results * Company focusing on critically ill hospitalized patientsTORONTO, ON / ACCESSWIRE / November 4, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Polish regulators have approved a clinical trial application for the investigational use of the company's monoclonal antibody candidate, designated EB05, as a single-dose t

    10/21/2021EDSA
    EDSA: Additional Favorable Mortality Reductions Identified in COVID-19 Trial…

    By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Additional Mortality Benefits Identified in Phase 2 COVID-19 Trial On October 19, 2021, Edesa Biotech, Inc. (NASDAQ:EDSA) announced additional results from the Phase 2 portion of the ongoing Phase 2/3 clinical trial of EB05 in critically ill COVID-19 patients. Last month, the independent Data and Safety Monitoring

    10/19/2021EDSA
    Why Edesa Biotech Shares Are Trading Higher Today

    Edesa Biotech Inc (NASDAQ: EDSA) is trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in COVID-19. Edesa reported that EB05 demonstrated mortality reductions in multiple patient groups beyond the initial findings. The company said it believes EB05 regulates the overactive and dysfunctional immune response associated with Acute Respiratory Distress Syndrome, which is the leading cause of death in COVID-19 patients. "

    10/19/2021EDSA
    Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study

    * Mortality reductions demonstrated across multiple patient groups * Additional efficacy signals recorded in a broad range of mild to severe ARDS patients * Company to focus on critically ill population for Phase 3TORONTO, ON / ACCESSWIRE / October 19, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced additional results from the Phase 2 part of an ongoing Phase 2/3 clinical study evaluating th

    10/9/2021EDSA
    As Edesa Biotech, Inc. (NASDAQ:EDSA) gains 11%, insiders who bought last year may be wishing they had bet higher

    Edesa Biotech, Inc. ( NASDAQ:EDSA ) insiders who bought shares over the past year were rewarded handsomely last week...

    09/22/2021EDSA
    50 Biggest Movers From Yesterday

    Check out these big penny stock gainers and losers Losers Edesa Biotech, Inc. (NASDAQ: EDSA) shares dipped 29.9% to close at $8.36 on profit-taking after the stock rallied over 100% yesterday. uCloudlink Group Inc. (NASDAQ: UCL) dropped 17.4% to close at $5.08 after gaining 14% on Monday. Movano Inc. (NASDAQ: MOVE) fell 16.4% to settle at $3.22. KULR Technology Group, Inc. (NYSE: KULR) declined 13.2% to settle at $2.37. ATIF Holdings Limited (NASDAQ: ATIF) fell 12.9% to settle at $3.4850. RBC Be

    09/20/2021EDSA
    Why Edesa Biotech Shares Are Soaring Today

    Edesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over standard of care. An independent Data and Safety Monitoring Board concluded that "a clinically important efficacy signal" was detected and that the study "met its objective." The DSMB recommended continuation of the study into